The path to an RSV vaccine

Current Opinion in Virology

Volumn 3, Issue 3, 2013, Pages 332-342

  Shaw, Christine A ^a   Ciarlet, Max ^a   Cooper, Brian W ^a   Dionigi, Lamberto ^a   Keith, Paula ^a   O'Brien, Karen B ^a   Rafie Kolpin, Maryam ^a   Dormitzer, Philip R ^a  

^a Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ARTICLE; DEVELOPED COUNTRY; DISEASE SEVERITY; EXPERIMENTAL MODEL; HUMAN; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION;

EID: 84880282032     PISSN: 18796257     EISSN: 18796265     Source Type: Journal    
DOI: 10.1016/j.coviro.2013.05.003     Document Type: Review

References (84)

1. G.J. Escobar, A. Ragins, S.X. Li, L. Prager, A.S. Masaquel, and P. Kipnis Recurrent wheezing in the third year of life among children born at 32 weeks' gestation or later: relationship to laboratory-confirmed, medically attended infection with respiratory syncytial virus during the first year of life Arch Pediatr Adolesc Med 164 2010 915 922
2. P. Wu, and T.V. Hartert Evidence for a causal relationship between respiratory syncytial virus infection and asthma Expert Rev Anti Infect Ther 9 2011 731 745
3. W.P. Glezen, L.H. Taber, A.L. Frank, and J.A. Kasel Risk of primary infection and reinfection with respiratory syncytial virus Am J Dis Child 140 1986 543 546
4. C.B. Hall, G.A. Weinberg, M.K. Iwane, A.K. Blumkin, K.M. Edwards, M.A. Staat, P. Auinger, M.R. Griffin, K.A. Poehling, and D. Erdman The burden of respiratory syncytial virus infection in young children N Engl J Med 360 2009 588 598
5. H. Nair, D.J. Nokes, B.D. Gessner, M. Dherani, S.A. Madhi, R.J. Singleton, K.L. O'Brien, A. Roca, P.F. Wright, and N. Bruce Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis Lancet 375 2010 1545 1555
6. A.R. Falsey, P.A. Hennessey, M.A. Formica, C. Cox, and E.E. Walsh Respiratory syncytial virus infection in elderly and high-risk adults N Engl J Med 352 2005 1749 1759
7. R.H. Parrott, H.W. Kim, J.O. Arrobio, D.S. Hodes, B.R. Murphy, C.D. Brandt, E. Camargo, and R.M. Chanock Epidemiology of respiratory syncytial virus infection in Washington D.C. II. Infection and disease with respect to age, immunologic status, race and sex Am J Epidemiol 98 1973 289 300
8. C.B. Hall, C.E. Long, and K.C. Schnabel Respiratory syncytial virus infections in previously healthy working adults Clin Infect Dis 33 2001 792 796
9. Diagnosis and management of bronchiolitis Pediatrics 118 2006 1774 1793
10. W.A. Prescott Jr., F. Doloresco, J. Brown, and J.A. Paladino Cost effectiveness of respiratory syncytial virus prophylaxis: a critical and systematic review Pharmacoeconomics 28 2010 279 293
11. B.S. Graham Biological challenges and technological opportunities for respiratory syncytial virus vaccine development Immunol Rev 239 2011 149 166
12. L.J. Anderson, P.R. Dormitzer, D.J. Nokes, R. Rappuol, A. Roca, and Graham BS Strategic priorities for respiratory syncytial virus (RSV) vaccine development Vaccine 31S2 2013 B209 B215
13. H.W. Kim, J.G. Canchola, C.D. Brandt, G. Pyles, R.M. Chanock, K. Jensen, and R.H. Parrott Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine Am J Epidemiol 89 1969 422 434
14. F.W. Henderson, A.M. Collier, W.A. Clyde Jr., and F.W. Denny Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children N Engl J Med 300 1979 530 534
15. J. Chin, R.L. Magoffin, L.A. Shearer, J.H. Schieble, and E.H. Lennette Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population Am J Epidemiol 89 1969 449 463
16. V.A. Fulginiti, J.J. Eller, O.F. Sieber, J.W. Joyner, M. Minamitani, and G. Meiklejohn Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine Am J Epidemiol 89 1969 435 448
17. A.Z. Kapikian, R.H. Mitchell, R.M. Chanock, R.A. Shvedoff, and C.E. Stewart An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine Am J Epidemiol 89 1969 405 421
18. M.E. Waris, C. Tsou, D.D. Erdman, D.B. Day, and L.J. Anderson Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV J Virol 71 1997 6935 6939
19. J.L. Hurwitz Respiratory syncytial virus vaccine development Expert Rev Vaccines 10 2011 1415 1433
20. P.F. Wright, R.A. Karron, R.B. Belshe, J.R. Shi, V.B. Randolph, P.L. Collins, A.F. O'Shea, W.C. Gruber, and B.R. Murphy The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines Vaccine 25 2007 7372 7378
21. M. Gomez, M.A. Mufson, F. Dubovsky, C. Knightly, W. Zeng, and G. Losonsky Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children Pediatr Infect Dis J 28 2009 655 658
22. H.W. Kim, S.L. Leikin, J. Arrobio, C.D. Brandt, R.M. Chanock, and R.H. Parrott Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection Pediatr Res 10 1976 75 78
23. J.R. Groothuis, E.A. Simoes, M.J. Levin, C.B. Hall, C.E. Long, W.J. Rodriguez, J. Arrobio, H.C. Meissner, D.R. Fulton, and R.C. Welliver Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group N Engl J Med 329 1993 1524 1530
24. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group Pediatrics 102 1998 531 537
25. F.P. Polack, M.N. Teng, P.L. Collins, G.A. Prince, M. Exner, H. Regele, D.D. Lirman, R. Rabold, S.J. Hoffman, and C.L. Karp A role for immune complexes in enhanced respiratory syncytial virus disease J Exp Med 196 2002 859 865
26. M.J. Cannon, P.J. Openshaw, and B.A. Askonas Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus J Exp Med 168 1988 1163 1168
27. G.A. Prince, S.J. Curtis, K.C. Yim, and D.D. Porter Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine J Gen Virol 82 2001 2881 2888
28. C.A. Shaw, J.R. Galarneau, K.E. Bowenkamp, K.A. Swanson, G.A. Palmer, G. Palladino, J.E. Markovits, N.M. Valiante, P.R. Dormitzer, and G.R. Otten The role of non-viral antigens in the cotton rat model of respiratory syncytial virus vaccine-enhanced disease Vaccine 31 2013 306 312
29. P.A. Piedra, H.S. Faden, G. Camussi, D.T. Wong, and P.L. Ogra Mechanism of lung injury in cotton rats immunized with formalin-inactivated respiratory syncytial virus Vaccine 7 1989 34 38
30. A. Boelen, A. Andeweg, J. Kwakkel, W. Lokhorst, T. Bestebroer, J. Dormans, and T. Kimman Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice Vaccine 19 2000 982 991
31. J.F. Valarcher, and G. Taylor Bovine respiratory syncytial virus infection Vet Res 38 2007 153 180
32. C. Orvell, E. Norrby, and M.A. Mufson Preparation and characterization of monoclonal antibodies directed against five structural components of human respiratory syncytial virus subgroup B J Gen Virol 68 Pt 12 1987 3125 3135
33. A.F. Antonis, R.S. Schrijver, F. Daus, P.J. Steverink, N. Stockhofe, E.J. Hensen, J.P. Langedijk, and R.G. van der Most Vaccine-induced immunopathology during bovine respiratory syncytial virus infection: exploring the parameters of pathogenesis J Virol 77 2003 12067 12073
34. K. West, L. Petrie, D.M. Haines, C. Konoby, E.G. Clark, K. Martin, and J.A. Ellis The effect of formalin-inactivated vaccine on respiratory disease associated with bovine respiratory syncytial virus infection in calves Vaccine 17 1999 809 820
35. N. Wood, and C.A. Siegrist Neonatal immunization: where do we stand? Curr Opin Infect Dis 24 2011 190 195
36. V.J. Philbin, and O. Levy Developmental biology of the innate immune response: implications for neonatal and infant vaccine development Pediatr Res 65 2009 98R 105R
37. J.E. Crowe Jr. Influence of maternal antibodies on neonatal immunization against respiratory viruses Clin Infect Dis 33 2001 1720 1727
38. W.P. Glezen, A. Paredes, J.E. Allison, L.H. Taber, and A.L. Frank Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level J Pediatr 98 1981 708 715
39. P.A. Piedra, A.M. Jewell, S.G. Cron, R.L. Atmar, and W.P. Glezen Correlates of immunity to respiratory syncytial virus (RSV) associated- hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies Vaccine 21 2003 3479 3482
40. T.M. de Sierra, M.L. Kumar, T.E. Wasser, B.R. Murphy, and E.K. Subbarao Respiratory syncytial virus-specific immunoglobulins in preterm infants J Pediatr 122 1993 787 791
41. N.E. Simister Placental transport of immunoglobulin G Vaccine 21 2003 3365 3369
42. G.A. Prince, R.L. Horswood, and R.M. Chanock Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats J Virol 55 1985 517 520
43. G.R. Siber, D. Leombruno, J. Leszczynski, J. McIver, D. Bodkin, R. Gonin, C.M. Thompson, E.E. Walsh, P.A. Piedra, and V.G. Hemming Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin J Infect Dis 169 1994 1368 1373
44. H. Blencowe, J. Lawn, J. Vandelaer, M. Roper, and S. Cousens Tetanus toxoid immunization to reduce mortality from neonatal tetanus Int J Epidemiol 39 Suppl 1 2010 i102 i109
45. M.C. Steinhoff, S.B. Omer, E. Roy, S. El Arifeen, R. Raqib, C. Dodd, R.F. Breiman, and K. Zaman Neonatal outcomes after influenza immunization during pregnancy: a randomized controlled trial Can Med Assoc J 184 2012 645 653
46. W. Buraphacheep, and W.M. Sullender The guinea pig as a model for the study of maternal immunization against respiratory syncytial virus infections in infancy J Infect Dis 175 1997 935 938
47. F.M. Munoz, P.A. Piedra, and W.P. Glezen Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women Vaccine 21 2003 3465 3467
48. R. Ochola, C. Sande, G. Fegan, P.D. Scott, G.F. Medley, P.A. Cane, and D.J. Nokes The level and duration of RSV-specific maternal IgG in infants in Kilifi Kenya PLoS ONE 4 2009 e8088
49. A.H. Brandenburg, J. Groen, H.A. van Steensel-Moll, E.C. Claas, P.H. Rothbarth, H.J. Neijens, and A.D. Osterhaus Respiratory syncytial virus specific serum antibodies in infants under six months of age: limited serological response upon infection J Med Virol 52 1997 97 104
50. R.B. Belshe, C.S. Ambrose, and T. Yi Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age Vaccine 26 suppl. 4 2008 D10 D16
51. B.G. Jones, R.E. Sealy, R. Rudraraju, V.L. Traina-Dorge, B. Finneyfrock, A. Cook, T. Takimoto, A. Portner, and J.L. Hurwitz Sendai virus-based RSV vaccine protects African green monkeys from RSV infection Vaccine 30 2012 959 968
52. D.I. Bernstein, E. Malkin, N. Abughali, J. Falloon, T. Yi, and F. Dubovsky Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children Pediatr Infect Dis J 31 2012 109 114
53. A. Krause, Y. Xu, S. Ross, W. Wu, J. Joh, and S. Worgall Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine Virol J 8 2011 375
54. M.B. Elliott, T. Chen, N.B. Terio, S.Y. Chong, R. Abdullah, A. Luckay, M.A. Egan, L.A. Boutilier, K. Melville, and R.A. Lerch Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques Vaccine 25 2007 7132 7144
55. A.J. Geall, A. Verma, G.R. Otten, C.A. Shaw, A. Hekele, K. Banerjee, Y. Cu, C.W. Beard, L.A. Brito, and T. Krucker Nonviral delivery of self-amplifying RNA vaccines Proc Natl Acad Sci USA 109 2012 14604 14609
56. M.A. Kutzler, and D.B. Weiner DNA vaccines: ready for prime time? Nat Rev Genet 9 2008 776 788
57. D. Kim, D. Huey, M. Oglesbee, and S. Niewiesk Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies Blood 117 2011 6143 6151
58. C.A. Siegrist, C. Barrios, X. Martinez, C. Brandt, M. Berney, M. Cordova, J. Kovarik, and P.H. Lambert Influence of maternal antibodies on vaccine responses: inhibition of antibody but not T cell responses allows successful early prime-boost strategies in mice Eur J Immunol 28 1998 4138 4148
59. B.R. Murphy, and E.E. Walsh Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity J Clin Microbiol 26 1988 1595 1597
60. A. Moghaddam, W. Olszewska, B. Wang, J.S. Tregoning, R. Helson, Q.J. Sattentau, and P.J. Openshaw A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines Nat Med 12 2006 905 907
61. K.A. Swanson, E.C. Settembre, C.A. Shaw, A.K. Dey, R. Rappuoli, C.W. Mandl, P.R. Dormitzer, and A. Carfi Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers Proc Natl Acad Sci USA 108 2011 9619 9624
62. G. Smith, R. Raghunandan, Y. Wu, Y. Liu, M. Massare, M. Nathan, B. Zhou, H. Lu, S. Boddapati, and J. Li Respiratory syncytial virus fusion glycoprotein expressed in insect cells form protein nanoparticles that induce protective immunity in cotton rats PLoS ONE 7 2012 e50852
63. G.M. Glenn, G. Smith, L. Fries, R. Raghunandan, H. Lu, B. Zhou, D.N. Thomas, S.P. Hickman, E. Kpamegan, and S. Boddapati Safety and immunogenicity of a Sf9 insect cell-derived respiratory syncytial virus fusion protein nanoparticle vaccine Vaccine 31 2013 524 532
64. H.S. Yin, R.G. Paterson, X. Wen, R.A. Lamb, and T.S. Jardetzky Structure of the uncleaved ectodomain of the paramyxovirus (hPIV3) fusion protein Proc Natl Acad Sci USA 102 2005 9288 9293
65. H.S. Yin, X. Wen, R.G. Paterson, R.A. Lamb, and T.S. Jardetzky Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation Nature 439 2006 38 44
66. M. Magro, V. Mas, K. Chappell, M. Vazquez, O. Cano, D. Luque, M.C. Terron, J.A. Melero, and C. Palomo Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention Proc Natl Acad Sci USA 2012
67. J.S. McLellan, Y. Yang, B.S. Graham, and P.D. Kwong Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes J Virol 85 2011 7788 7796
68. L.J. Calder, L. Gonzalez-Reyes, B. Garcia-Barreno, S.A. Wharton, J.J. Skehel, D.C. Wiley, and J.A. Melero Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies Virology 271 2000 122 131
69. K. Ludwig, B. Schade, C. Bottcher, T. Korte, N. Ohlwein, B. Baljinnyam, M. Veit, and A. Herrmann Electron cryomicroscopy reveals different F1 + F2 protein states in intact parainfluenza virions J Virol 82 2008 3775 3781
70. J. Wrammert, K. Smith, J. Miller, W.A. Langley, K. Kokko, C. Larsen, N.Y. Zheng, I. Mays, L. Garman, and C. Helms Rapid cloning of high-affinity human monoclonal antibodies against influenza virus Nature 453 2008 667 671
71. M. Bonsignori, S.M. Alam, H.X. Liao, L. Verkoczy, G.D. Tomaras, B.F. Haynes, and M.A. Moody HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design Trends Microbiol 20 2012 532 539
72. N. Jiang, J. He, J.A. Weinstein, L. Penland, S. Sasaki, X.S. He, C.L. Dekker, N.Y. Zheng, M. Huang, and M. Sullivan Lineage structure of the human antibody repertoire in response to influenza vaccination Sci Transl Med 5 2013 171ra119
73. S.A. Feldman, S. Audet, and J.A. Beeler The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate J Virol 74 2000 6442 6447
74. E.A. Kurt-Jones, L. Popova, L. Kwinn, L.M. Haynes, L.P. Jones, R.A. Tripp, E.E. Walsh, M.W. Freeman, D.T. Golenbock, and L.J. Anderson Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus Nat Immunol 1 2000 398 401
75. J.A. Beeler, and K. van Wyke Coelingh Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function J Virol 63 1989 2941 2950
76. J.S. McLellan, B.E. Correia, M. Chen, Y. Yang, B.S. Graham, W.R. Schief, and P.D. Kwong Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus J Mol Biol 409 2011 853 866
77. P.J. Openshaw, S.L. Clarke, and F.M. Record Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G Int Immunol 4 1992 493 500
78. T.R. Johnson, M.N. Teng, P.L. Collins, and B.S. Graham Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV J Virol 78 2004 6024 6032
79. S.M. Varga, X. Wang, R.M. Welsh, and T.J. Braciale Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4(+) T cells Immunity 15 2001 637 646
80. A. Bukreyev, L. Yang, and P.L. Collins The secreted G protein of human respiratory syncytial virus antagonizes antibody-mediated restriction of replication involving macrophages and complement J Virol 86 2012 10880 10884
81. R.A. Tripp, L.P. Jones, L.M. Haynes, H. Zheng, P.M. Murphy, and L.J. Anderson CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein Nat Immunol 2 2001 732 738
82. H. Caidi, J.L. Harcourt, R.A. Tripp, L.J. Anderson, and L.M. Haynes Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice PLoS ONE 7 2012 e51485
83. M.F. Delgado, S. Coviello, A.C. Monsalvo, G.A. Melendi, J.Z. Hernandez, J.P. Batalle, L. Diaz, A. Trento, H.Y. Chang, and W. Mitzner Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease Nat Med 15 2009 34 41
84. J. Paavonen, P. Naud, J. Salmeron, C.M. Wheeler, S.N. Chow, D. Apter, H. Kitchener, X. Castellsague, J.C. Teixeira, and S.R. Skinner Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women Lancet 374 2009 301 314